Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...

Greater baseline disease pruritus and quality of life impairment are associated with higher rates of super response to dupilumab in patients with AD.

A new injectable medicine is giving hope to people with asthma by helping them breathe better. The drug, called dupilumab ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Dr S. Shahzad Mustafa looks ahead to ACAAI 2025, which will highlight advances in chronic urticaria treatment and ...

A cohort study finds no significant differences in height among children with inflammatory diseases treated with JAK ...

During the third quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $663 million, as Treasury Stock. As of September 30, 2025, $2.156 billion ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Regeneron Pharmaceuticals and Sanofi SA have initiated a new clinical study titled ‘An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to ...